“…IFX remains an effective biologic drug for both PsO and PsA patients, but its infusions were difficult to deliver during COVID‐19 pandemic due to both patient‐related (i.e., COVID‐19 phobia or Cabin fever syndrome) and hospital‐related (i.e., infusions room unavailability) causes. 14 Furthermore, during pandemic chronic patients undergoing immunosuppressive drugs globally decreased their compliance 6 due to media disinformation and fake news, 15 discordant position on therapies, COVID‐19, and related outcomes. 3 , 4 , 16 , 17 In line with National Psoriasis Foundation recommendations, 18 The Italian Society of Dermatology (SIDeMaST) suggested not to discontinue biologics in absence of COVID‐19, 19 while in case of COVID‐19, symptomatic or asymptomatic, positions remain still discordant.…”